# A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

> **NCT04866485** · PHASE1 · UNKNOWN · sponsor: **Harbour BioMed (Guangzhou) Co. Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HBM4003 and pembrolizumab

## Key facts

- **NCT ID:** NCT04866485
- **Lead sponsor:** Harbour BioMed (Guangzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-14
- **Primary completion:** 2023-02
- **Final completion:** 2023-02
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2021-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866485, "A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04866485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*